Utility of inflammatory makers, alanine aminotransferase, aspartate aminotransferase, and procalcitonin tests in COVID-19


  • Shkar Rzgar K.Rostam Department of Biology, College of Science, University of Sulaimani, Iraq.
  • Khattab Ahmed Mustafa Shekhany Department of Biology, College of Science, University of Sulaimani, Iraq.
  • Hardi Rafat Baqi Baqi Department of Medical Laboratory Technology, Shaqlawa Technical College, Erbil Polytechnic University, Erbil, Iraq.




COVID-19, SARS-CoV-2, Ferritin, Procalcitonin, Alanine aminotransferase, Aspartate aminotransferase


Background and objective: Many tests are conducted for monitoring the progression and the severity of coronavirus disease (COVID-19) infection. However, the extent to which these tests are helpful in clinical practice and therapeutics of COVID-19 is still ambiguous. This study aimed to evaluate the feasibility of performing inflammatory marker tests, liver function tests, and procalcitonin test in the diagnosis and monitoring of COVID-19 infection.

Methods: The current study compares the results of alanine aminotransferase, aspartate aminotransferase, ferritin, and procalcitonin tests in two different populations of 123 COVID-19 suspects and a control group of 110 healthy individuals in Erbil city of Kurdistan region of Iraq to search for possible significant differences in both groups.

Results: The COVID-19 group had significantly higher ferritin and procalcitonin mean values than the control group (P = 0.001). The differences between alanine aminotransferase and aspartate aminotransferase were significant in some age and gender classes of both groups. However, the overall differences were not statistically significant (P = 0.339 and 0.286, respectively).

Conclusion: The outcome of the current study suggests that among the group of tests conducted for the study population, the most useful tests are ferritin and procalcitonin to monitor the COVID-19 patients' health status.


Metrics Loading ...


Worldometers. COVID-19 Coronavirus Pandemic 2020. (Accessed October 23, 2020, available at https://www.worldometers.info/coronavirus/).

WHO. Coronavirus disease (COVID19) 2020.(Accessed October 20, 2020, available at https://www.who.int/emergencies/diseases/novel coronavirus2019/question-and-answers-hub/qadetail/q-a-coronaviruses).

Zeng F, Yuzhao H, Ying G, Mingzhu Y, Xiang C, Liang X, et al. Association of inflammatory markers with the severity of COVID-19 A meta-analysis. Int J Infect Dis. 2020;96:467–74. https://doi.org/10.1016/j.ijid.2020.05.055.

Tay MZ, Poh CM, Rénia L, MacAry PA, LFP Ng. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. https://doi.org/10.1038/s41577-020-0311-8.

Bertolini A, de Peppel IP, Frank AJA B, Han M, Alberto F, Fabio F, et al. Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–72. https://doi.org/10.1002/hep.31480.

Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051. https://doi.org/10.1016/j.ijantimicag.2020.106051.

Dennis J, McGovern A, Vollmer S, Mateen BA. Improving survival of critical care patients with Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020. Crit Care Med. 2021;49(2):209–14. https://doi.org/10.1097/CCM.0000000000004747.

Beigel JH, Kay MT, Lori ED, Aneesh KM, Barry SZ, Andre CK, et al. Remdesivir for the treatment of Covid-19: Final Report. N Engl J Med. 2020;383:1813–26. https://doi.org/10.1056/NEJMoa200764.

Salari N, Amin H, Rostam J, Aliakbar V, Shna R, Masoud M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. Global Health. 2020;16(1):57. https://doi.org/10.1186/s12992-020-00589-w.

Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica. 2020;44:e72. https://doi.org/10.26633/rpsp.2020.72.

Zhou B, She J, Wang Y, Ma X. Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 Novel Coronavirus Disease. Res Sq. 2020. https://doi.org/10.21203/rs.3.rs-18079/v1.

Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19) A meta-analysis. Clin Chim Acta. 2020;505:190–1. https://doi.org/10.1016/j.cca.2020.03.004.

Ali N. Relationship between COVID-19 infection and liver injury. A review of recent data. Frontiers in Medicine 2020;7:458. https://doi.org/10.3389/fmed.2020.00458.

Fan Z, Liping C, Jun L, Xin C, Jingmao Y, Cheng T, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–6. https://doi.org/10.1016/j.cgh.2020.04.002.




How to Cite

K.Rostam, S. R., Shekhany, K. A. M. ., & Baqi, H. R. B. (2022). Utility of inflammatory makers, alanine aminotransferase, aspartate aminotransferase, and procalcitonin tests in COVID-19. Zanco Journal of Medical Sciences (Zanco J Med Sci), 26(1), 22–28. https://doi.org/10.15218/zjms.2022.003



Original Articles